 |
|
|
| |
Switch from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir DF: Efficacy and Pharmacokinetics
|
| |
| |
Reported by Jules Levin
ICAAC 2013 Denver Colorado Sept 10-13
C Cohen1, R Elion2, P Ruane3, D Shamblaw4, E DeJesus5, B Rashbaum6, J Custodio7, S Ramanathan7, M Fordyce7, MS Rhee7, B Kearney7, J Szwarcberg7
1Community Research Initiative, Boston, MA, US; 2Whitman Walker Clinic, Washington, DC, US; 3Peter J. Ruane, MD, Inc., Los Angeles, CA, US; 4La Playa Medical Group and Clinical Research, San Diego, CA, US;
5Orlando Immunology Center, Orlando, FL, US; 6Capital Medical Associates PC, Washington, DC, US; 7Gilead Sciences, Foster City, CA, US
|
| |
|
|
|
|
|
